Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017 (2017), Article ID 4754827, 15 pages
https://doi.org/10.1155/2017/4754827
Review Article

Challenging a Misnomer? The Role of Inflammatory Pathways in Inflammatory Breast Cancer

1Olivia Newton-John Cancer Research Institute and La Trobe University School of Cancer Medicine, Heidelberg, VIC 3084, Australia
2Austin Health, Heidelberg, VIC 3084, Australia

Correspondence should be addressed to Belinda Yeo; ua.gro.ircjno@oeY.adnileB

Received 3 February 2017; Accepted 18 April 2017; Published 21 May 2017

Academic Editor: Yona Keisari

Copyright © 2017 Riley J. Morrow et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Lerebours, I. Bieche, and R. Lidereau, “Update on inflammatory breast cancer,” Breast Cancer Research, vol. 7, no. 2, pp. 52–58, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Cariati, T. M. Bennett-Britton, S. E. Pinder, and A. D. Purushotham, ““Inflammatory” breast cancer,” Surgical Oncology, vol. 14, no. 3, pp. 133–143, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. K. W. Hance, W. F. Anderson, S. S. Devesa, H. A. Young, and P. H. Levine, “Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute,” Journal of the National Cancer Institute, vol. 97, no. 13, pp. 966–975, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Chang, S. L. Parker, T. Pham, A. U. Buzdar, and S. D. Hursting, “Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992,” Cancer, vol. 82, no. 12, pp. 2366–2372, 1998. View at Publisher · View at Google Scholar
  6. M. M. Mohamed, D. Al-Raawi, S. F. Sabet, and M. El-Shinawi, “Inflammatory breast cancer: new factors contribute to disease etiology: a review,” Journal of Advanced Research, vol. 5, no. 5, pp. 525–536, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. C. G. Kleer, K. L. van Golen, and S. D. Merajver, “Molecular biology of breast cancer metastasis: inflammatory breast cancer: clinical syndrome and molecular determinants,” Breast Cancer Research, vol. 2, no. 6, pp. 423–429, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Dawood, S. D. Merajver, P. Viens et al., “International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment,” Annals of Oncology, vol. 22, no. 3, pp. 515–523, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. W. A. Woodward and M. Cristofanilli, “Inflammatory breast cancer,” Seminars in Radiation Oncology, vol. 19, no. 4, pp. 256–265, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. J. M. Matro, T. Li, M. Cristofanilli et al., “Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome,” Clinical Breast Cancer, vol. 15, no. 1, pp. 1–7, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Li, A. M. Gonzalez-Angulo, P. K. Allen et al., “Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer,” The Oncologist, vol. 16, no. 12, pp. 1675–1683, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Bertucci, P. Finetti, J. Rougemont et al., “Gene expression profiling identifies molecular subtypes of inflammatory breast cancer,” Cancer Research, vol. 65, no. 6, pp. 2170–2178, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Yamauchi, W. A. Woodward, V. Valero et al., “Inflammatory breast cancer: what we know and what we need to learn,” The Oncologist, vol. 17, no. 7, pp. 891–899, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Bertucci, N. T. Ueno, P. Finetti et al., “Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival,” Annals of Oncology, vol. 25, no. 2, pp. 358–365, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. F. M. Robertson, M. Bondy, W. Yang et al., “Inflammatory breast cancer: the disease, the biology, the treatment,” CA: A Cancer Journal for Clinicians, vol. 60, no. 6, pp. 351–375, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. D. J. van Uden, H. W. van Laarhoven, A. H. Westenberg, J. H. de Wilt, and C. F. Blanken-Peeters, “Inflammatory breast cancer: an overview,” Critical Reviews in Oncology/Hematology, vol. 93, no. 2, pp. 116–126, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Gianni, T. Pienkowski, Y. H. Im et al., “Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial,” The Lancet Oncology, vol. 13, no. 1, pp. 25–32, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Dawood, X. Lei, R. Dent et al., “Survival of women with inflammatory breast cancer: a large population-based study,” Annals of Oncology, vol. 25, no. 6, pp. 1143–1151, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. I. Bieche, F. Lerebours, S. Tozlu, M. Espie, M. Marty, and R. Lidereau, “Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature,” Clinical Cancer Research, vol. 10, no. 20, pp. 6789–6795, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Van Laere, I. Van der Auwera, G. Van den Eynden et al., “Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using affymetrix-based genome-wide gene-expression analysis,” British Journal of Cancer, vol. 97, no. 8, pp. 1165–1174, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. J. S. Ross, S. M. Ali, K. Wang et al., “Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations,” Breast Cancer Research and Treatment, vol. 154, no. 1, pp. 155–162, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. J. M. Goldfarb and J. E. Pippen, “Inflammatory breast cancer: the experience of Baylor University Medical Center at Dallas,” Proceedings (Baylor University. Medical Center), vol. 24, no. 2, pp. 86–88, 2011. View at Google Scholar
  23. K. Shin and S. H. Lee, “Interplay between inflammatory responses and lymphatic vessels,” Immune Network, vol. 14, no. 4, pp. 182–186, 2014. View at Publisher · View at Google Scholar
  24. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-related inflammation,” Nature, vol. 454, no. 7203, pp. 436–444, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Shostak and A. Chariot, “NF-kappaB, stem cells and breast cancer: the links get stronger,” Breast Cancer Research, vol. 13, no. 4, p. 214, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Hoffmann and D. Baltimore, “Circuitry of nuclear factor kappaB signaling,” Immunological Reviews, vol. 210, pp. 171–186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Hoffmann, A. Levchenko, M. L. Scott, and D. Baltimore, “The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation,” Science, vol. 298, no. 5596, pp. 1241–1245, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Bodmer, D. Brors, K. Pak et al., “Inflammatory signals increase Fas ligand expression by inner ear cells,” Journal of Neuroimmunology, vol. 129, no. 1-2, pp. 10–17, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. R. H. Shih, C. Y. Wang, and C. M. Yang, “NF-kappaB signaling pathways in neurological inflammation: a mini review,” Frontiers in Molecular Neuroscience, vol. 8, p. 77, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Gardam, F. Sierro, A. Basten, F. Mackay, and R. Brink, “TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor,” Immunity, vol. 28, no. 3, pp. 391–401, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. A. P. Grech, M. Amesbury, T. Chan, S. Gardam, A. Basten, and R. Brink, “TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells,” Immunity, vol. 21, no. 5, pp. 629–642, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Silke and R. Brink, “Regulation of TNFRSF and innate immune signalling complexes by TRAFs and cIAPs,” Cell Death and Differentiation, vol. 17, no. 1, pp. 35–45, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. T. U. Barbie, G. Alexe, A. R. Aref et al., “Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth,” The Journal of Clinical Investigation, vol. 124, no. 1, pp. 5411–5423, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Nakshatri, P. Bhat-Nakshatri, D. A. Martin, R. J. Goulet Jr., and G. W. Sledge Jr., “Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth,” Molecular and Cellular Biology, vol. 17, no. 7, pp. 3629–3639, 1997. View at Publisher · View at Google Scholar
  35. Y. Xia, S. Shen, and I. M. Verma, “NF-kappaB, an active player in human cancers,” Cancer Immunology Research, vol. 2, no. 9, pp. 823–830, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Karin, Y. Cao, F. R. Greten, and Z. W. Li, “NF-kappaB in cancer: from innocent bystander to major culprit,” Nature Reviews. Cancer, vol. 2, no. 4, pp. 301–310, 2002. View at Publisher · View at Google Scholar
  37. M. Yu, X. Zhou, L. Niu et al., “Targeting transmembrane TNF-alpha suppresses breast cancer growth,” Cancer Research, vol. 73, no. 13, pp. 4061–4074, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. V. Pileczki, C. Braicu, C. D. Gherman, and I. Berindan-Neagoe, “TNF-α gene knockout in triple negative breast cancer cell line induces apoptosis,” International Journal of Molecular Sciences, vol. 14, no. 1, pp. 411–420, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. R. M. Hudziak, G. D. Lewis, M. R. Shalaby et al., “Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 14, pp. 5102–5106, 1988. View at Google Scholar
  40. M. F. Rubio, S. Werbajh, E. G. Cafferata et al., “TNF-alpha enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B,” Oncogene, vol. 25, no. 9, pp. 1367–1377, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Yin, X. Chen, and Y. Shu, “Gene expression of the invasive phenotype of TNF-alpha-treated MCF-7 cells,” Biomedicine & Pharmacotherapy, vol. 63, no. 6, pp. 421–428, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Gloire, E. Dejardin, and J. Piette, “Extending the nuclear roles of IkappaB kinase subunits,” Biochemical Pharmacology, vol. 72, no. 9, pp. 1081–1089, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. S. M. Sheen-Chen, W. J. Chen, H. L. Eng, and F. F. Chou, “Serum concentration of tumor necrosis factor in patients with breast cancer,” Breast Cancer Research and Treatment, vol. 43, no. 3, pp. 211–215, 1997. View at Publisher · View at Google Scholar · View at Scopus
  44. F. Lerebours, S. Vacher, C. Andrieu et al., “NF-kappa B genes have a major role in inflammatory breast cancer,” BMC Cancer, vol. 8, no. 1, p. 41, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Van Laere, I. Van der Auwera, G. G. Van den Eynden et al., “Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis,” Breast Cancer Research and Treatment, vol. 93, no. 3, pp. 237–246, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. S. J. Van Laere, I. Van der Auwera, G. G. Van den Eynden et al., “Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding,” Clinical Cancer Research, vol. 12, no. (11 Part 1), pp. 3249–3256, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. M. F. Kendellen, J. W. Bradford, C. L. Lawrence, K. S. Clark, and A. S. Baldwin, “Canonical and non-canonical NF-kappaB signaling promotes breast cancer tumor-initiating cells,” Oncogene, vol. 33, no. 10, pp. 1297–1305, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Jhaveri, E. Teplinsky, D. Silvera et al., “Hyperactivated mTOR and JAK2/STAT3 pathways: molecular drivers and potential therapeutic targets of inflammatory and invasive ductal breast cancers after neoadjuvant chemotherapy,” Clinical Breast Cancer, vol. 16, no. 2, pp. 113–122.e1, 2016. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Li, R. M. Thomas, H. Suzuki, J. K. De Brabander, X. Wang, and P. G. Harran, “A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death,” Science, vol. 305, no. 5689, pp. 1471–1474, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. J. E. Vince, D. Chau, B. Callus et al., “TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha,” The Journal of Cell Biology, vol. 182, no. 1, pp. 171–184, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. K. M. Aird, X. Ding, A. Baras et al., “Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression,” Molecular Cancer Therapeutics, vol. 7, no. 1, pp. 38–47, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. J. L. Allensworth, S. J. Sauer, H. K. Lyerly, M. A. Morse, and G. R. Devi, “Smac mimetic birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-alpha-independent mechanism,” Breast Cancer Research and Treatment, vol. 137, no. 2, pp. 359–371, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. J. E. Goldberg and K. L. Schwertfeger, “Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics,” Current Drug Targets, vol. 11, no. 9, pp. 1133–1146, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. A. W. Studebaker, G. Storci, J. L. Werbeck et al., “Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner,” Cancer Research, vol. 68, no. 21, pp. 9087–9095, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. K. L. Streicher, N. E. Willmarth, J. Garcia, J. L. Boerner, T. G. Dewey, and S. P. Ethier, “Activation of a nuclear factor kappaB/interleukin-1 positive feedback loop by amphiregulin in human breast cancer cells,” Molecular Cancer Research, vol. 5, no. 8, pp. 847–861, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. H. Watanabe, O. Gaide, V. Petrilli et al., “Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity,” The Journal of Investigative Dermatology, vol. 127, no. 8, pp. 1956–1963, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. J. E. Vince and J. Silke, “The intersection of cell death and inflammasome activation,” Cellular and Molecular Life Sciences, vol. 73, no. 11-12, pp. 2349–2367, 2016. View at Publisher · View at Google Scholar · View at Scopus
  58. K. E. Lawlor, N. Khan, A. Mildenhall et al., “RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL,” Nature Communications, vol. 6, p. 6282, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. K. M. Aird, R. B. Ghanayem, S. Peplinski, H. K. Lyerly, and G. R. Devi, “X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor,” Molecular Cancer Therapeutics, vol. 9, no. 5, pp. 1432–1442, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Fukada, T. Ohtani, Y. Yoshida et al., “STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition,” The EMBO Journal, vol. 17, no. 22, pp. 6670–6677, 1998. View at Publisher · View at Google Scholar
  61. K. Imada and W. J. Leonard, “The Jak-STAT pathway,” Molecular Immunology, vol. 37, no. 1, pp. 1–11, 2000. View at Publisher · View at Google Scholar · View at Scopus
  62. J. J. Babon, L. N. Varghese, and N. A. Nicola, “Inhibition of IL-6 family cytokines by SOCS3,” Seminars in Immunology, vol. 26, no. 1, pp. 13–19, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Berishaj, S. P. Gao, S. Ahmed et al., “Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer,” Breast Cancer Research, vol. 9, no. 3, p. R32, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. P. C. Heinrich, I. Behrmann, G. Muller-Newen, F. Schaper, and L. Graeve, “Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway,” The Biochemical Journal, vol. 334, no. Part 2, pp. 297–314, 1998. View at Google Scholar
  65. A. Jarnicki, T. Putoczki, and M. Ernst, “Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?” Cell division, vol. 5, no. 1, p. 14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. J. Bromberg, “Stat proteins and oncogenesis,” The Journal of Clinical Investigation, vol. 109, no. 9, pp. 1139–1142, 2002. View at Publisher · View at Google Scholar
  67. Q. Chang, E. Bournazou, P. Sansone et al., “The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis,” Neoplasia, vol. 15, no. 7, pp. 848–862, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. I. Barbieri, S. Pensa, T. Pannellini et al., “Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten,” Cancer Research, vol. 70, no. 6, pp. 2558–2567, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. L. Ma, B. Zhao, R. A. Walgren, J. R. Clayton, and T. P. Burkholder, “Abstract 2820: LY2784544, a small molecule JAK2 inhibitor, induces apoptosis in inflammatory breast cancer spheres through targeting IL-6-JAK-STAT3 pathway,” Cancer Research, vol. 71, no. 8 Supplement, pp. 2820–2820, 2011. View at Publisher · View at Google Scholar
  70. B. G. Debeb, E. N. Cohen, K. Boley et al., “Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells,” Breast Cancer Research and Treatment, vol. 134, no. 2, pp. 495–510, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. C. Dethlefsen, G. Hojfeldt, and P. Hojman, “The role of intratumoral and systemic IL-6 in breast cancer,” Breast Cancer Research and Treatment, vol. 138, no. 3, pp. 657–664, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. D. Drygin, C. B. Ho, M. Omori et al., “Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer,” Biochemical and Biophysical Research Communications, vol. 415, no. 1, pp. 163–167, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Badache and N. E. Hynes, “Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells,” Cancer Research, vol. 61, no. 1, pp. 383–391, 2001. View at Google Scholar
  74. L. Chen, L. M. Shulman, and M. Revel, “IL-6 receptors and sensitivity to growth inhibition by IL-6 in clones of human breast carcinoma cells,” Journal of Biological Regulators and Homeostatic Agents, vol. 5, no. 4, pp. 125–136, 1991. View at Google Scholar
  75. I. Tamm, I. Cardinale, J. Krueger, J. S. Murphy, L. T. May, and P. B. Sehgal, “Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells,” The Journal of Experimental Medicine, vol. 170, no. 5, pp. 1649–1669, 1989. View at Publisher · View at Google Scholar
  76. D. Iliopoulos, H. A. Hirsch, G. Wang, and K. Struhl, “Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 4, pp. 1397–1402, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. K. L. van Golen, Z. F. Wu, X. T. Qiao, L. Bao, and S. D. Merajver, “RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells,” Neoplasia, vol. 2, no. 5, pp. 418–425, 2000. View at Publisher · View at Google Scholar
  78. D. Conze, L. Weiss, P. S. Regen et al., “Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells,” Cancer Research, vol. 61, no. 24, pp. 8851–8858, 2001. View at Google Scholar
  79. H. Korkaya, G. I. Kim, A. Davis et al., “Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population,” Molecular Cell, vol. 47, no. 4, pp. 570–584, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. R. Rodriguez-Barrueco, J. Yu, L. P. Saucedo-Cuevas et al., “Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR−/HER2+ breast cancers,” Genes & Development, vol. 29, no. 15, pp. 1631–1648, 2015. View at Publisher · View at Google Scholar · View at Scopus
  81. Z. C. Hartman, X. Y. Yang, O. Glass et al., “HER2 overexpression elicits a pro-inflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis,” Cancer Research, vol. 71, no. 13, pp. 4380–4391, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. H. Yamauchi and N. T. Ueno, “Targeted therapy in inflammatory breast cancer,” Cancer, vol. 116, 11 Supplement, pp. 2758-2759, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. D. Zhang, T. A. LaFortune, S. Krishnamurthy et al., “EGFR tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer,” Clinical Cancer Research, vol. 15, no. 21, pp. 6639–6648, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. C. L. Buchheit, B. L. Angarola, A. Steiner, K. J. Weigel, and Z. T. Schafer, “Anoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestration,” Cell Death and Differentiation, vol. 22, no. 8, pp. 1275–1286, 2015. View at Publisher · View at Google Scholar · View at Scopus
  85. xE. Paplomata and R. O'Regan, “The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers,” Therapeutic Advances in Medical Oncology, vol. 6, no. 4, pp. 154–166, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. N. Todorović-Raković and J. Milovanović, “Interleukin-8 in breast cancer progression,” Journal of Interferon & Cytokine Research, vol. 33, no. 10, pp. 563–570, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. J. K. Singh, B. M. Simoes, S. J. Howell, G. Farnie, and R. B. Clarke, “Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells,” Breast Cancer Research, vol. 15, no. 4, p. 210, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. M. M. Mohamed, “Monocytes conditioned media stimulate fibronectin expression and spreading of inflammatory breast cancer cells in three-dimensional culture: a mechanism mediated by IL-8 signaling pathway,” Cell Communication and Signaling: CCS, vol. 10, no. 1, pp. 3–3, 2012. View at Publisher · View at Google Scholar
  89. D. Mazhar, R. Gillmore, and J. Waxman, “COX and cancer,” QJM: An International Journal of Medicine, vol. 98, no. 10, pp. 711–718, 2005. View at Publisher · View at Google Scholar · View at Scopus
  90. N. Yoshimura, H. Sano, M. Okamoto et al., “Expression of cyclooxygenase-1 and -2 in human breast cancer,” Surgery Today, vol. 33, no. 11, pp. 805–811, 2003. View at Publisher · View at Google Scholar · View at Scopus
  91. R. A. Karmali, S. Welt, H. T. Thaler, and F. Lefevre, “Prostaglandins in breast cancer: relationship to disease stage and hormone status,” British Journal of Cancer, vol. 48, no. 5, pp. 689–696, 1983. View at Publisher · View at Google Scholar · View at Scopus
  92. P. H. Rolland, P. M. Martin, J. Jacquemier, A. M. Rolland, and M. Toga, “Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells,” Journal of the National Cancer Institute, vol. 64, no. 5, pp. 1061–1070, 1980. View at Google Scholar
  93. M. Parrett, R. Harris, F. Joarder, M. Ross, K. Clausen, and F. Robertson, “Cyclooxygenase-2 gene expression in human breast cancer,” International Journal of Oncology, vol. 10, no. 3, pp. 503–507, 1997. View at Google Scholar
  94. A. Ristimaki, A. Sivula, J. Lundin et al., “Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer,” Cancer Research, vol. 62, no. 3, pp. 632–635, 2002. View at Google Scholar
  95. K. Subbaramaiah, L. Norton, W. Gerald, and A. J. Dannenberg, “Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3,” The Journal of Biological Chemistry, vol. 277, no. 21, pp. 18649–18657, 2002. View at Publisher · View at Google Scholar · View at Scopus
  96. F. M. Robertson, A. M. Simeone, A. Mazumdar et al., “Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells,” Journal of Experimental Therapeutics & Oncology, vol. 7, no. 4, pp. 299–312, 2008. View at Google Scholar
  97. J. W. Pollard, “Macrophages define the invasive microenvironment in breast cancer,” Journal of Leukocyte Biology, vol. 84, no. 3, pp. 623–630, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. R. A. Mukhtar, O. Nseyo, M. J. Campbell, and L. J. Esserman, “Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics,” Expert Review of Molecular Diagnostics, vol. 11, no. 1, pp. 91–100, 2011. View at Publisher · View at Google Scholar · View at Scopus
  99. J. Condeelis and J. W. Pollard, “Macrophages: obligate partners for tumor cell migration, invasion, and metastasis,” Cell, vol. 124, no. 2, pp. 263–266, 2006. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Mantovani, T. Schioppa, C. Porta, P. Allavena, and A. Sica, “Role of tumor-associated macrophages in tumor progression and invasion,” Cancer Metastasis Reviews, vol. 25, no. 3, pp. 315–322, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. A. R. Wolfe, N. J. Trenton, B. G. Debeb et al., “Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models,” Oncotarget, vol. 7, no. 50, pp. 82482–82492, 2016. View at Publisher · View at Google Scholar · View at Scopus
  102. D. Al-Raawi, H. Abu-El-Zahab, M. El-Shinawi, and M. M. Mohamed, “Membrane type-1 matrix metalloproteinase (MT1-MMP) correlates with the expression and activation of matrix metalloproteinase-2 (MMP-2) in inflammatory breast cancer,” International Journal of Clinical and Experimental Medicine, vol. 4, no. 5, pp. 265–275, 2011. View at Google Scholar
  103. M. A. Nouh, M. M. Mohamed, M. El-Shinawi et al., “Cathepsin B: a potential prognostic marker for inflammatory breast cancer,” Journal of Translational Medicine, vol. 9, no. 1, pp. 1–1, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. M. M. Mohamed, E. A. El-Ghonaimy, M. A. Nouh, R. J. Schneider, B. F. Sloane, and M. El-Shinawi, “Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties,” The International Journal of Biochemistry & Cell Biology, vol. 46, pp. 138–147, 2014. View at Publisher · View at Google Scholar · View at Scopus
  105. E. J. Wherry, “T cell exhaustion,” Nature Immunology, vol. 12, no. 6, pp. 492–499, 2011. View at Google Scholar
  106. F. Bertucci, P. Finetti, C. Colpaert et al., “PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy,” Oncotarget, vol. 6, no. 15, pp. 13506–13519, 2015. View at Publisher · View at Google Scholar
  107. C. A. Hamm, D. Moran, K. Rao et al., “Genomic and immunological tumor profiling identifies targetable pathways and extensive CD8+/PDL1+ immune infiltration in inflammatory breast cancer tumors,” Molecular Cancer Therapeutics, vol. 15, no. 7, pp. 1746–1756, 2016. View at Publisher · View at Google Scholar · View at Scopus
  108. D. Zhang and K. A. Kilian, “The effect of mesenchymal stem cell shape on the maintenance of multipotency,” Biomaterials, vol. 34, no. 16, pp. 3962–3969, 2013. View at Publisher · View at Google Scholar · View at Scopus
  109. S. Liu, C. Ginestier, S. J. Ou et al., “Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks,” Cancer Research, vol. 71, no. 2, pp. 614–624, 2011. View at Publisher · View at Google Scholar · View at Scopus
  110. C. Zhang, W. E. I. Zhai, Y. A. N. Xie, Q. Chen, W. E. I. Zhu, and X. Sun, “Mesenchymal stem cells derived from breast cancer tissue promote the proliferation and migration of the MCF-7 cell line in vitro,” Oncology Letters, vol. 6, no. 6, pp. 1577–1582, 2013. View at Publisher · View at Google Scholar · View at Scopus
  111. A. E. Karnoub, A. B. Dash, A. P. Vo et al., “Mesenchymal stem cells within tumour stroma promote breast cancer metastasis,” Nature, vol. 449, no. 7162, pp. 557–563, 2007. View at Publisher · View at Google Scholar · View at Scopus
  112. H. J. Li, F. Reinhardt, H. R. Herschman, and R. A. Weinberg, “Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling,” Cancer Discovery, vol. 2, no. 9, pp. 840–855, 2012. View at Publisher · View at Google Scholar · View at Scopus
  113. K. M. McAndrews, D. J. McGrail, N. Ravikumar, and M. R. Dawson, “Mesenchymal stem cells induce directional migration of invasive breast cancer cells through TGF-β,” Scientific Reports, vol. 5, p. 16941, 2015. View at Publisher · View at Google Scholar · View at Scopus
  114. L. Lacerda, B. G. Debeb, D. Smith et al., “Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model,” Breast Cancer Research, vol. 17, no. 1, p. 42, 2015. View at Publisher · View at Google Scholar · View at Scopus
  115. A. H. Klopp, L. Lacerda, A. Gupta et al., “Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells,” PloS One, vol. 5, no. 8, article e12180, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. N. A. Lobo, Y. Shimono, D. Qian, and M. F. Clarke, “The biology of cancer stem cells,” Annual Review of Cell and Developmental Biology, vol. 23, pp. 675–699, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. C. T. Jordan, M. L. Guzman, and M. Noble, “Cancer stem cells,” The New England Journal of Medicine, vol. 355, no. 12, pp. 1253–1261, 2006. View at Publisher · View at Google Scholar · View at Scopus
  118. M. A. Velasco-Velázquez, V. M. Popov, M. P. Lisanti, and R. G. Pestell, “The role of breast cancer stem cells in metastasis and therapeutic implications,” The American Journal of Pathology, vol. 179, no. 1, pp. 2–11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  119. K. Polyak and R. A. Weinberg, “Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits,” Nature Reviews. Cancer, vol. 9, no. 4, pp. 265–273, 2009. View at Publisher · View at Google Scholar · View at Scopus
  120. S. Kotiyal and S. Bhattacharya, “Breast cancer stem cells, EMT and therapeutic targets,” Biochemical and Biophysical Research Communications, vol. 453, no. 1, pp. 112–116, 2014. View at Publisher · View at Google Scholar · View at Scopus
  121. M. Luo, M. Brooks, and M. S. Wicha, “Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance,” Current Pharmaceutical Design, vol. 21, no. 10, pp. 1301–1310, 2015. View at Publisher · View at Google Scholar
  122. E. Charafe-Jauffret, C. Ginestier, F. Iovino et al., “Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature,” Cancer Research, vol. 69, no. 4, pp. 1302–1313, 2009. View at Publisher · View at Google Scholar · View at Scopus
  123. Y. Xiao, Y. Ye, K. Yearsley, S. Jones, and S. H. Barsky, “The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype,” The American Journal of Pathology, vol. 173, no. 2, pp. 561–574, 2008. View at Publisher · View at Google Scholar · View at Scopus
  124. N. J. McCarthy, X. Yang, I. R. Linnoila et al., “Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer,” Clinical Cancer Research, vol. 8, no. 12, pp. 3857–3862, 2002. View at Google Scholar
  125. C. G. Colpaert, P. B. Vermeulen, I. Benoy et al., “Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression,” British Journal of Cancer, vol. 88, no. 5, pp. 718–725, 2003. View at Publisher · View at Google Scholar · View at Scopus
  126. J. Y. Pierga, T. Petit, T. Delozier et al., “Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study,” The Lancet Oncology, vol. 13, no. 4, pp. 375–384, 2012. View at Publisher · View at Google Scholar · View at Scopus
  127. F. Bertucci, M. Fekih, A. Autret et al., “Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study,” The Lancet Oncology, vol. 17, no. 5, pp. 600–611, 2016. View at Publisher · View at Google Scholar · View at Scopus
  128. F. M. Robertson, A. M. Simeone, A. Lucci, J. S. McMurray, S. Ghosh, and M. Cristofanilli, “Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4,” Cancer, vol. 116, 11 Supplement, pp. 2806–2814, 2010. View at Publisher · View at Google Scholar · View at Scopus
  129. Q. Pan, C. G. Kleer, K. L. van Golen et al., “Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis,” Cancer Research, vol. 62, no. 17, pp. 4854–4859, 2002. View at Google Scholar
  130. Q. Pan, L. W. Bao, and S. D. Merajver, “Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade,” Molecular Cancer Research, vol. 1, no. 10, pp. 701–706, 2003. View at Google Scholar
  131. C. G. Kleer, K. L. van Golen, T. Braun, and S. D. Merajver, “Persistent E-cadherin expression in inflammatory breast cancer,” Modern Pathology, vol. 14, no. 5, pp. 458–464, 2001. View at Publisher · View at Google Scholar · View at Scopus
  132. E. N. Cohen, H. Gao, S. Anfossi et al., “Inflammation mediated metastasis: immune induced epithelial-to-mesenchymal transition in inflammatory breast cancer cells,” PloS One, vol. 10, no. 7, article e0132710, 2015. View at Publisher · View at Google Scholar · View at Scopus
  133. H. Boussen, M. Cristofanilli, T. Zaks, M. DeSilvio, V. Salazar, and N. Spector, “Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer,” Journal of Clinical Oncology, vol. 28, no. 20, pp. 3248–3255, 2010. View at Publisher · View at Google Scholar · View at Scopus
  134. G. Goh, R. Schmid, K. Guiver et al., “Clonal evolutionary analysis during HER2 blockade in HER2-positive inflammatory breast cancer: a phase II open-label clinical trial of afatinib +/− vinorelbine,” PLoS Medicine, vol. 13, no. 12, article e1002136, 2016. View at Publisher · View at Google Scholar · View at Scopus
  135. S. Verstovsek, R. A. Mesa, J. Gotlib et al., “Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I,” Haematologica, vol. 100, no. 4, pp. 479–488, 2015. View at Publisher · View at Google Scholar · View at Scopus
  136. Y. Okuda, “Review of tocilizumab in the treatment of rheumatoid arthritis,” Biologics, vol. 2, no. 1, pp. 75–82, 2008. View at Google Scholar
  137. A. Kaneko, “Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy,” Therapeutic Advances in Chronic Disease, vol. 4, no. 1, pp. 15–21, 2013. View at Publisher · View at Google Scholar · View at Scopus
  138. S. Abrous-Anane, A. Savignoni, C. Daveau et al., “Management of inflammatory breast cancer after neoadjuvant chemotherapy,” International Journal of Radiation Oncology, Biology, Physics, vol. 79, no. 4, pp. 1055–1063, 2011. View at Publisher · View at Google Scholar · View at Scopus
  139. H. Masuda, T. M. Brewer, D. D. Liu et al., “Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes,” Annals of Oncology, vol. 25, no. 2, pp. 384–391, 2014. View at Publisher · View at Google Scholar · View at Scopus
  140. M. Panades, I. A. Olivotto, C. H. Speers et al., “Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis,” Journal of Clinical Oncology, vol. 23, no. 9, pp. 1941–1950, 2005. View at Publisher · View at Google Scholar · View at Scopus
  141. V. C. Do Nascimento, R. Rajan, A. Redfern, and C. Saunders, “Inflammatory breast cancer: a decade of experience,” Asia-Pacific Journal of Clinical Oncology, vol. 12, no. 3, pp. 242–247, 2016. View at Publisher · View at Google Scholar · View at Scopus
  142. V. Bonev, M. Evangelista, J. H. Chen et al., “Long-term follow-up of breast-conserving therapy in patients with inflammatory breast cancer treated with neoadjuvant chemotherapy,” The American Surgeon, vol. 80, no. 10, pp. 940–943, 2014. View at Google Scholar
  143. A. Gogia, V. Raina, S. V. Deo, N. K. Shukla, B. K. Mohanti, and D. N. Sharma, “Inflammatory breast cancer: a single centre analysis,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 7, pp. 3207–3210, 2014. View at Publisher · View at Google Scholar · View at Scopus